Disclosure: This article may contain affiliate links. If you click a link and make a purchase, we may receive a commission at no additional cost to you. All opinions remain our own.
By HollyHerman.com Editorial Team. This guide is based on editorial research of cited public sources. It is not a record of product testing, personal use, or medical review.
In This Article
What AREDS2 was built to do
AREDS2 is not a general eye vitamin plan. It is a high-dose formula studied for one narrow use. It may slow the move from intermediate AMD to advanced AMD.
AMD is an age-related disease of the retina. The retina is the light-sensing layer at the back of the eye. Advanced AMD can harm central vision. Central vision is the sharp sight used for reading and seeing faces.
The National Eye Institute AREDS and AREDS2 trial report, last updated October 22, 2025, says the formulas cut the risk of progression from intermediate to advanced AMD by about 25 percent.
That finding has firm limits. AREDS and AREDS2 did not prevent AMD from starting. They did not lower cataract risk. A cataract is a cloudy eye lens that can blur sight.
The National Eye Institute AREDS2 supplement guide, last updated June 22, 2021, says AREDS2 may slow vision loss for people with intermediate AMD. It may also help when late AMD is in one eye only.
Who took part in the studies
The study group matters. AREDS2 enrolled 4,203 people aged 50 to 85. They had intermediate AMD in both eyes. Or they had intermediate AMD in one eye and advanced AMD in the other.
People without AMD were not the focus. People with early AMD were also left out. Earlier AREDS results had not found a benefit for them.
So, the trial does not prove the formula helps every adult. It does not prove it improves normal eyesight. It does not show that it stops early AMD from becoming intermediate AMD.
It also does not replace care for wet AMD. Wet AMD is a late form of AMD. It involves unusual, fragile blood vessels under the retina. The NEI guide notes that wet AMD may have other treatment options.
What the trials found
The first AREDS trial tested vitamin C, vitamin E, beta-carotene, zinc, and copper. In people at high risk, the full formula cut advanced AMD risk by about 25 percent versus placebo.
A placebo is a pill with no active ingredients. It lets researchers compare groups more fairly.
AREDS2 tested changes to the older formula. It looked at lutein and zeaxanthin. It also tested omega-3 fats and a lower zinc amount.
Adding omega-3 fats did not improve the overall AMD result. It did not help cataracts either. Lutein and zeaxanthin also showed no added overall effect in the first group-wide comparison.
Still, the formula with lutein and zeaxanthin instead of beta-carotene showed an added benefit in trial analysis. It also avoided beta-carotene. That ingredient raised a lung cancer concern for people who smoke or used to smoke.
This was a risk-reduction result. It was not a promise of better vision. It also was not proof that every product called “eye support” has the same effect.
How the trial formula compares with labels
The formula matters. “Contains lutein” does not mean “matches AREDS2.” The NEI lists these AREDS2 amounts:
- Vitamin C: 500 milligrams
- Vitamin E: 400 international units, or IU
- Zinc: 80 milligrams
- Copper: 2 milligrams
- Lutein: 10 milligrams
- Zeaxanthin: 2 milligrams
- Beta-carotene: none
Copper was included because high zinc can lower copper levels. The trial report says lower zinc did not cause a meaningful change in effectiveness.
A regular multivitamin is not automatically an AREDS2 formula. The NEI guide says regular multivitamins do not have the same mix or amounts.
A label can show whether a finished product matches the studied formula. Check for each nutrient and each amount. A front-label claim alone cannot show a match.
Five kinds of evidence to keep apart
Eye-supplement claims can blend different questions together. Keeping them apart makes the claims easier to judge.
- Regulation: This asks how a product type is overseen. The supplied sources do not give a full guide to supplement regulation. This article makes no broad regulation claim.
- Category evidence: This asks whether a type of supplement helped in a study. AREDS2 has evidence for certain people with AMD.
- Ingredient evidence: This asks what one nutrient does. It does not prove that a blend will work.
- Finished-product evidence: This asks whether the exact formula and dose were studied. Familiar ingredients do not make a product an AREDS2 match.
- User reports: These are personal stories. They may raise questions. They cannot prove cause and effect.
The NIH Office of Dietary Supplements vitamin A fact sheet, updated March 10, 2025, says vitamin A supports normal vision. It also says vitamin A deficiency is rare in the United States.
That is ingredient context. It does not show that extra vitamin A prevents AMD. It does not show that it fixes blurry vision. It does not replace the full AREDS2 formula studied in higher-risk AMD.
Safety limits that matter
AREDS2 uses large amounts of vitamins and minerals. The NEI says these supplements may affect digestion. They may also change how other medicines work in the body.
The older AREDS formula has beta-carotene. Current and former smokers should avoid that older formula and use AREDS2 instead. The trial report found more lung cancer among former smokers using a formula with beta-carotene.
Vitamin A needs its own caution. The ODS fact sheet says too much preformed vitamin A can cause severe headache, blurred vision, nausea, dizziness, and other harm. Preformed vitamin A is found in some supplements and medicines.
High-dose preformed vitamin A can cause birth defects. The fact sheet says people who are pregnant or may become pregnant should not take high-dose preformed vitamin A supplements.
Medicine interactions also matter. The ODS lists orlistat, acitretin, and bexarotene as examples that can affect vitamin A use or levels. The NEI advises discussing all medicines, vitamins, and supplements with a doctor before starting AREDS2.
Common questions
Can AREDS2 prevent AMD?
No. The National Eye Institute says AREDS and AREDS2 did not prevent AMD from starting. The evidence concerns slower progression in certain higher-risk stages.
Can AREDS2 help cataracts?
No benefit for cataracts was found in these trials. AREDS and AREDS2 also did not lower the overall need for cataract surgery.
Does lutein alone have the same evidence as AREDS2?
No. Lutein is one part of the AREDS2 formula. The trial evidence concerns the full formula and the people studied. It does not cover every lutein-only product.
Should people who smoked choose the older AREDS formula?
No. The National Eye Institute says current and former smokers should choose AREDS2. The older AREDS formula contains beta-carotene.
Related reviews and editorial record
If you want to compare how individual products present eye-health claims, these separate editorial reviews may help: our review of Night Vision Pro eyewear claims and the VisiFlora supplement label review. They are not proof of product effects.
Source dates: National Eye Institute AREDS and AREDS2 trial report, last updated October 22, 2025; National Eye Institute AREDS2 supplement guide, last updated June 22, 2021; NIH Office of Dietary Supplements vitamin A fact sheet, updated March 10, 2025.
Fact-checked: 2026-08-19. Reviewer status: Editorial research review based on the sources cited above; not a medical review. Next review: 2027-02-15.
This article is general education, not diagnosis or individualized medical advice. Consult a qualified professional about your personal risks or treatment.
Leave a Reply
You must be logged in to post a comment.